| Name | Title | Contact Details |
|---|
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
Synecor is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.